News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
810,793 Results
Type
Article (79608)
Company Profile (449)
Press Release (730736)
Multimedia
Podcasts (117)
Webinars (14)
Section
Business (224060)
Career Advice (3416)
Deals (38651)
Drug Delivery (128)
Drug Development (89538)
Employer Resources (191)
FDA (17694)
Job Trends (16827)
News (382645)
Policy (37930)
Tag
Academia (2990)
Academic (1)
Accelerated approval (6)
Adcomms (29)
Allergies (95)
Alliances (54832)
ALS (106)
Alzheimer's disease (1505)
Antibody-drug conjugate (ADC) (161)
Approvals (17650)
Artificial intelligence (307)
Autoimmune disease (29)
Automation (17)
Bankruptcy (397)
Best Places to Work (12558)
BIOSECURE Act (21)
Biosimilars (120)
Biotechnology (309)
Bladder cancer (86)
Brain cancer (31)
Breast cancer (312)
Cancer (2484)
Cardiovascular disease (211)
Career advice (2900)
Career pathing (34)
CAR-T (178)
Cell therapy (488)
Cervical cancer (22)
Clinical research (72378)
Collaboration (933)
Company closure (2)
Compensation (584)
Complete response letters (30)
COVID-19 (2867)
CRISPR (50)
C-suite (276)
Cystic fibrosis (109)
Data (2386)
Decentralized trials (2)
Denatured (38)
Depression (56)
Diabetes (301)
Diagnostics (6861)
Digital health (20)
Diversity (9)
Diversity, equity & inclusion (46)
Drug discovery (129)
Drug pricing (130)
Drug shortages (33)
Duchenne muscular dystrophy (104)
Earnings (92914)
Editorial (47)
Employer branding (25)
Employer resources (163)
Events (125053)
Executive appointments (792)
FDA (19128)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (829)
Gene editing (125)
Generative AI (28)
Gene therapy (362)
GLP-1 (862)
Government (5094)
Grass and pollen (6)
Guidances (158)
Healthcare (20800)
Huntington's disease (26)
IgA nephropathy (31)
Immunology and inflammation (155)
Indications (30)
Infectious disease (3031)
Inflammatory bowel disease (159)
Inflation Reduction Act (10)
Influenza (57)
Intellectual property (103)
Interviews (638)
IPO (17593)
IRA (50)
Job creations (4723)
Job search strategy (2390)
Kidney cancer (11)
Labor market (45)
Layoffs (563)
Leadership (24)
Legal (9504)
Liver cancer (82)
Lung cancer (350)
Lymphoma (162)
Machine learning (9)
Management (63)
Manufacturing (363)
MASH (85)
Medical device (14605)
Medtech (14610)
Mergers & acquisitions (21637)
Metabolic disorders (809)
Multiple sclerosis (90)
NASH (23)
Neurodegenerative disease (118)
Neuropsychiatric disorders (34)
Neuroscience (2127)
NextGen: Class of 2025 (7517)
Non-profit (5070)
Now hiring (41)
Obesity (432)
Opinion (275)
Ovarian cancer (84)
Pain (105)
Pancreatic cancer (91)
Parkinson's disease (164)
Partnered (24)
Patents (261)
Patient recruitment (119)
Peanut (51)
People (63469)
Pharmaceutical (97)
Pharmacy benefit managers (22)
Phase I (22340)
Phase II (31512)
Phase III (23718)
Pipeline (1420)
Policy (178)
Postmarket research (3384)
Preclinical (9997)
Press Release (72)
Prostate cancer (114)
Psychedelics (38)
Radiopharmaceuticals (269)
Rare diseases (437)
Real estate (6950)
Recruiting (74)
Regulatory (25702)
Reports (52)
Research institute (2642)
Resumes & cover letters (543)
Rett syndrome (6)
RNA editing (5)
RSV (50)
Schizophrenia (84)
Series A (144)
Series B (94)
Service/supplier (19)
Sickle cell disease (59)
Special edition (20)
Spinal muscular atrophy (166)
Sponsored (34)
Startups (4189)
State (2)
Stomach cancer (16)
Supply chain (76)
Tariffs (56)
The Weekly (77)
Vaccines (820)
Venture capitalists (45)
Weight loss (307)
Women's health (40)
Worklife (20)
Date
Today (182)
Last 7 days (1029)
Last 30 days (3291)
Last 365 days (34634)
2025 (12629)
2024 (37520)
2023 (42453)
2022 (53784)
2021 (58559)
2020 (57500)
2019 (51099)
2018 (38891)
2017 (36473)
2016 (37024)
2015 (42860)
2014 (37298)
2013 (34660)
2012 (36198)
2011 (36235)
2010 (35731)
Location
Africa (1123)
Alabama (55)
Alaska (7)
Arizona (260)
Arkansas (14)
Asia (47014)
Australia (8174)
California (6645)
Canada (2103)
China (579)
Colorado (288)
Connecticut (306)
Delaware (165)
Europe (107579)
Florida (984)
Georgia (226)
Hawaii (1)
Idaho (63)
Illinois (617)
India (28)
Indiana (344)
Iowa (11)
Japan (177)
Kansas (112)
Kentucky (26)
Louisiana (14)
Maine (69)
Maryland (985)
Massachusetts (5066)
Michigan (236)
Minnesota (427)
Mississippi (2)
Missouri (92)
Montana (31)
Nebraska (25)
Nevada (70)
New Hampshire (69)
New Jersey (1869)
New Mexico (31)
New York (1880)
North Carolina (1129)
North Dakota (9)
Northern California (2893)
Ohio (221)
Oklahoma (15)
Oregon (40)
Pennsylvania (1469)
Puerto Rico (14)
Rhode Island (36)
South America (1504)
South Carolina (26)
South Dakota (1)
Southern California (2482)
Tennessee (108)
Texas (993)
United States (25305)
Utah (199)
Virginia (167)
Washington D.C. (72)
Washington State (598)
West Virginia (3)
Wisconsin (60)
810,793 Results for "st jude medical inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
BioLineRx Announces Clinical Trial Agreement with St. Jude Children’s Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)
BioLineRx Ltd. today announced a multi-center Phase 1 clinical trial sponsored by St. Jude Children’s Research Hospital, Inc. to evaluate motixafortide for the mobilization of CD34+ hematopoietic stem cells (HSCs) used in the development of gene therapies for patients with sickle cell disease (SCD).
May 30, 2024
·
8 min read
Drug Development
CalciMedica Collaborator St. Jude Children’s Research Hospital Presents Data from Initial Cohort of CRSPA Study at 65th Annual ASH Meeting & Exposition
CalciMedica Inc. today announced that its collaborator, St. Jude Children’s Research Hospital (SJCRH), presented data from the initial cohort of the Phase 1/2 CRSPA study of Auxora™ (zegocractin injectable emulsion) in asparaginase-induced pancreatic toxicity (AIPT).
December 11, 2023
·
9 min read
Press Releases
New Research from Children’s Hospital of Philadelphia and St. Jude Poised to Transform Approach to Diagnosing and Treating Acute Leukemia in Children
August 15, 2024
·
7 min read
Press Releases
Helius Medical Technologies, Inc. Announces Reimbursement by Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device
May 12, 2025
·
5 min read
Press Releases
Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease
February 27, 2025
·
6 min read
Press Releases
Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025
April 30, 2025
·
2 min read
Press Releases
Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference
May 8, 2025
·
1 min read
Xtant Medical to Participate in 21st Annual Craig-Hallum Institutional Investor Conference on May 29
Xtant Medical Holdings, Inc. today announced that Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will participate in the 21st Annual Craig-Hallum Institutional Investor Conference on May 29 in Minneapolis.
May 22, 2024
·
1 min read
Press Releases
Moderna to Present at Upcoming Bernstein’s 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025
May 8, 2025
·
1 min read
Press Releases
Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma
April 28, 2025
·
8 min read
1 of 81,080
Next
